Brisbane Times Ozempic maker sheds $US475b and weight-loss crown after disastrous trial
Analysts say Novo Nordisk’s new obesity drug may be obsolete before it hits the shelves, underlining a massive fall from grace for the company behind the weight loss boom.
Analysts say Novo Nordisk’s new obesity drug may be obsolete before it hits the shelves, underlining a massive fall from grace for the company behind the weight loss boom.